Articles tagged with Cancer Medication
Researchers from Tokyo University of Science reveal the crystal structure of centromere-associated protein E (CENP-E), a promising target for inhibitor therapy. The discovery is expected to facilitate the development of anticancer drugs with fewer adverse effects on patients.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
Research analysis reveals gaps and uncertainties in evidence base for cancer drugs, including lack of relevance and inconsistent reporting. Findings emphasize the importance of improving communication of benefits and harms to support informed decision-making by patients and clinicians.
A new drug combination has doubled the expected time until cancer progression in heavily resistant head and neck cancer patients. The treatment, which includes a monoclonal antibody drug called ficlatuzumab, has shown an unusually high response rate of 38% in HPV-negative patients.
Researchers developed a 3D cell culture system to test fibroblast inhibitors with anti-cancer drugs. Combining nintedanib with cisplatin increased the latter's efficacy in suppressing cancer growth and invasion. The study provides a promising tool for preclinical drug testing.
Researchers from China have identified inosine as a potential broad-spectrum anti-inflammatory agent that improves survival in mice infected with SARS-CoV-2. The study also highlights TBK1 as a promising target for inhibiting cytokine storms and mitigating acute inflammatory lung injury.
The new medicine has shown promising results in a Phase 1 clinical trial, with 70% of patients stable after six weeks and one patient remaining stable for over two years. Developed by NTNU researcher Marit Otterlei, ATX-101 targets cancer cells' stress regulation system, leaving healthy cells unaffected.
A new study found that women with BRCA1 or BRCA2 mutations who are obese may experience higher rates of DNA damage in their breast tissue, which could contribute to breast cancer development. The researchers suggest that weight management and medications like metformin may be important for preventive care.
Researchers created a three-dimensional structure that mimics bone and houses osteosarcoma cells beside immune cells, finding increased inflammation reduces chemotherapy effectiveness. The study highlights the importance of the tumor microenvironment in disease progression and treatment.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Researchers have discovered how TKI cancer drugs cause inflammation, linking it to mitochondrial dysfunction and the NLRP3 inflammasome. The study found that all tested TKIs share a common off-target activity against mitochondrial SFKs.
Researchers at the Salk Institute discovered that combining two therapeutic drugs, entinostat and trametinib, can significantly reduce tumor volume and number in mice with LKB1-mutated non-small cell lung cancer. The findings could lead to clinical trials in humans and potentially transform treatment for cancers beyond NSCLC.
Researchers at Pusan National University have developed a novel FRET-based biosensor to detect double-strand breaks in DNA, providing real-time information on γH2AX. The sensor's sensitivity is higher than conventional immunostaining techniques, making it useful for identifying DNA damage factors and elucidating repair mechanisms.
A new review paper suggests that selective protection of normal cells from chemotherapy could increase the therapeutic window and improve outcomes for cancer patients. The authors propose using antagonistic drug combinations to kill drug-resistant cancer cells, reducing side effects and improving quality of life.
Researchers have developed a novel 3D covalent organic framework, TUS-64, with the largest pore size and lowest density ever recorded. The material shows promise as a drug nanocarrier vehicle, with high capacity to hold drugs and sustained release rate.
A new drug called CADD522 blocks a gene associated with driving bone cancer's spread, increasing survival rates by 50% in mice implanted with human bone cancer. The breakthrough treatment shows promise in all main bone cancer subtypes and has the potential to save lives and reduce disability.
A team of scientists has developed a novel, implantable drug delivery system that can be controlled by external light sources and is absorbable by the body. This technology has promising implications for treating various medical conditions, including pain management and cancer treatment.
The NCCN Annual Conference will debut a new hybrid format featuring in-person events at a new venue, allowing for hallway conversations and networking opportunities. The conference will also showcase more than 100 abstract poster presentations on various oncology-related categories.
Patients with stage IIIB-IV melanoma who received neoadjuvant pembrolizumab had a significantly lower risk of cancer recurrence compared to those receiving adjuvant therapy only. The study found improved event-free survival rates in the neoadjuvant group, suggesting that starting immunotherapy before surgery generates better outcomes.
Applying evolutionary principles to medicine inspires new ways of preventing and treating disease, including overcoming chemotherapy resistance and antibiotic resistance. Evolutionary-inspired strategies like 'anti-evolution' drugs and extinction therapy can tackle these global health threats.
Researchers at the Paul Scherrer Institute have developed a film that demonstrates the potential of photopharmacology in treating diseases such as cancer. The new approach uses light to switch on and off a molecular photoswitch, allowing for targeted and reversible drug action.
Researchers discovered that combining ferroptosis induction with immune checkpoint inhibition reduces liver tumour growth and metastases, offering a promising new approach for treating liver cancer
Researchers at University of Gothenburg developed AI method using graph theory and neural networks to analyze cell movement, enabling better understanding of biological processes and development of new medical technologies. The method can reconstruct cell paths and test medication effectiveness as potential cancer treatments.
Researchers found that gatekeeper mutations in kinases can destabilize the inactive form, making them more active and prone to cancer recurrence. This could inform which drugs oncologists use as a first-line treatment.
Researchers at Harvard's Wyss Institute developed a method to fine-tune CAR-T cell stimulation using artificial antigen-presenting scaffolds. This approach enhances consistency and potency of resulting CAR-T cell products, allowing for better cancer treatment outcomes.
A study published in the Journal of Urology found that using Mark Cuban's cost-plus drug pricing model could save Medicare an estimated $1.29 billion annually on urological drugs. This would lead to more affordable treatment options for patients and redirect taxpayer funds towards other important issues.
The NCI is funding a $587,000 research grant to improve KRAS treatment resistance in pancreatic cancer. Dr. Andrew Waters aims to develop personalized medicine approaches by studying unique resistance mechanisms.
A new study reveals that the immune system mounts a weak response to lung cancer due to an environment created by bacteria in the lymph nodes near the lungs. T-cell responses are suppressed by regulatory T cells and interferon gamma produced in response to commensal bacterial presence.
Researchers report an updated analysis from a phase I study of mivavotinib, a spleen tyrosine kinase inhibitor, in patients with relapsed/refractory B-cell lymphoma. The study showed a 45% overall response rate and median duration of response of 28.1 months in the overall cohort.
A study found that immune checkpoint inhibitors enhance chemotherapy-induced neuropathic pain by blocking interaction between macrophages and neurons via PD1-PDL1 synergy. This discovery could lead to the development of therapeutic alternatives to prevent pain while maintaining anti-neoplastic effects.
A research team led by Professor Kwang-Hyun Cho at KAIST has developed a fundamental technology to revert metastatic lung cancer cells to a non-metastatic state. This breakthrough could lead to the elimination of drug resistance and metastatic potential in cancer cells, while increasing their responsiveness to chemotherapy.
Scientists at MIT have designed a novel nanoparticle platform that can deliver optimal ratios of multiple cancer drugs, leading to enhanced efficacy and reduced side effects. The bottlebrush-shaped particles can be loaded with varying concentrations of drugs, enabling the precise delivery of synergistic combinations.
A study found a link between pain and indigestion medication purchases and ovarian cancer diagnoses, suggesting earlier symptom recognition. The research suggests that loyalty card data can be used to identify potential ovarian cancer cases.
Researchers seek to reduce medical errors among patients with limited English proficiency by implementing three different translation approaches. The goal is to compare the effectiveness of telephone interpreter-based and in-person interpreter-assisted communication in reducing errors.
Researchers found that female patients with diffuse large B-cell lymphoma treated in the afternoon had reduced mortality rates and cancer recurrence compared to those treated in the morning. The study suggests that timing chemotherapy delivery according to an individual's circadian clock may improve treatment outcomes.
A new study finds that andiroba oil accelerates wound healing, increases contraction rates, and promotes local re-epithelialization. The oil also presents a similar potential to low-level laser therapy (LLLT) in treating oral mucositis, a common side effect of chemotherapy.
Researchers have developed a new DNA sequencing method, Chem-map, which can precisely map where drugs bind to the genome. The technique enables detection of small molecule-genome interactions and provides insights into how life-saving drugs work in cancer treatment.
Researchers successfully applied AlphaFold AI to an end-to-end platform, discovering a novel target and developing a potent hit molecule for liver cancer. The study demonstrates the potential of AI-powered drug discovery to accelerate treatment development.
A new study led by Massachusetts General Hospital researchers reveals that an investigational drug called YTX-7739 can delay the growth of brain tumors and increase their sensitivity to conventional chemotherapy. The drug works by inhibiting de novo lipid synthesis, a process used by cancer cells for energy production.
A new genetic test has been developed to identify ovarian cancer patients who benefit from PARP inhibitors, a treatment option with significant improvements in prognosis. The test has been optimized for the Finnish population and is clinically approved, allowing for targeted treatment and reduced adverse effects.
A new study found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or total number of immune cells in and around a tumor. The findings suggest that six signatures of immune cell gene activation from B cells were associated with higher elimination rates and better survival outcomes.
A comprehensive study of childhood leukemia's genetic diversity provides insights into personalized therapy. Researchers identified distinct groups based on drug sensitivity profiles, which significantly impact prognosis.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Researchers from Okayama University found that Actinidia arguta (Sarunashi) juice and its component isoquercetin inhibit lung cancer development in mice, accelerating DNA repair and suppressing Akt-mediated growth signaling. The study suggests Sarunashi juice as an attractive candidate for chemoprevention.
The National Cancer Institute has approved atezolizumab, an immunotherapy drug, for the treatment of adults and children with advanced alveolar soft part sarcoma. The approval is based on a phase 2 trial that showed significant tumor shrinkage in about a third of patients.
A cost-effectiveness analysis of direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for cancer-associated thrombosis found that DOACs are more medically effective and cost-effective. The most cost-effective DOAC, apixaban, was also shown to be the least costly anticoagulant.
A new study examines the cost-effectiveness of anticoagulation strategies for blood clots in cancer patients, finding that direct oral anti-coagulant (DOAC) drugs are more effective and cost-effective than low molecular weight heparin (LMWH). DOACs were favored as being more effective and less costly than LMWH in base-case analysis but...
Researchers developed a cell-based method to predict breast cancer treatment responses, showing promising results and potential for personalized medicine. The method uses tumour cells and supporting cells from patients, allowing for efficient drug profiling and accurate treatment prediction.
Extracellular vesicles from immune cells have been shown to activate the immune system in mice with skin cancer, rendering them sensitive to checkpoint inhibitor therapy. The treatment improved survival rates when used in combination with checkpoint inhibitors.
A phase I clinical trial of PAC-1 found the drug to be well-tolerated, stalling tumor growth and reducing size in patients with end-stage cancers. The therapeutic activity was also observed against sarcomas, with minor side effects reported.
The Endocrine Society's Clinical Practice Guideline provides suggestions for the treatment of hypercalcemia of malignancy, a common and life-threatening metabolic complication of cancer. Treatment options include intravenous bisphosphonates or denosumab medications, with denosumab recommended as the preferred choice.
Researchers at Michigan Medicine have developed a new biomarker-based strategy to screen for immune checkpoint inhibitor-induced myocarditis, which can cause muscle damage and liver injury. Early detection of these biomarkers can lead to earlier treatment and improved survival rates.
The use of 3D-patient tumor avatars (3D-PTAs) is crucial for guiding treatment decisions in precision oncology. These avatars, including patient-derived organoids, 3D bioprinting, and microscale models, can accurately depict a tumor with its microenvironment, enabling the testing and prediction of therapeutic drug efficacy.
Researchers at the University of Tokyo have developed artificial DNA that can target and kill cancer cells by binding to microRNA molecules. The DNA triggers an immune response that not only kills cancer cells but also prevents further growth of cancerous tissue.
Researchers from the University of Cambridge have identified a method to track and kill resistant cancer cells in mice. By tagging different types of breast cancer cells with unique genetic barcodes, they were able to identify which cells are evading chemotherapy and target them specifically with a new treatment approach.
Researchers at Memorial Sloan Kettering Cancer Center discovered that common cancer treatments cause long-term damage to heart tissue by activating a key inflammatory signaling pathway. Inhibiting this pathway may reduce the risk of cancer survivors developing heart disease later in life.
The American Roentgen Ray Society has awarded the 2023 ARRS Gold Medal to Dr. Bernard F. King, Jr., MD, FACR, FSAR, in recognition of his distinguished service to radiology. Dr. King has made significant contributions to the field, including the development of contrast media recognition and treatment protocols.
Researchers identify CDK4 and filamin proteins as predictors of response to paclitaxel in HER2-negative breast cancer patients. High levels of these proteins are associated with a positive response rate in 90% of cases.
Researchers found that simultaneously targeting two signalling switches can severely inhibit tumour angiogenesis, cancer growth and metastasis in multiple models of cancer. This approach has the potential to restrict a cancer's ability to escape therapy by rapidly destroying the VEGF receptor when both receptors are targeted.
A randomized controlled trial found that a low-carbohydrate, high-fat diet helped patients with type 2 diabetes achieve better weight loss and glucose control over a 6-month intervention compared to a high-carb, low-fat diet. However, changes were not sustained 3 months after the intervention.